AACR: In redemption of the PI3K drug class, Bayer's Aliqopa leaps ahead of Gilead's Zydelig in lymphoma

The PI3K inhibitors were once viewed as a blockbuster opportunity in blood cancer. But patient deaths in clinical trials for earlier-line use of Gilead Sciences’ first-to-market Zydelig dashed that hope. Now, in what could be viewed as a redemption of the drug class, Bayer’s Aliqopa has come up with a success safely.